TW202128610A - 醫藥調配物 - Google Patents

醫藥調配物 Download PDF

Info

Publication number
TW202128610A
TW202128610A TW109136022A TW109136022A TW202128610A TW 202128610 A TW202128610 A TW 202128610A TW 109136022 A TW109136022 A TW 109136022A TW 109136022 A TW109136022 A TW 109136022A TW 202128610 A TW202128610 A TW 202128610A
Authority
TW
Taiwan
Prior art keywords
compound
particle size
size distribution
niclosamide
crystal
Prior art date
Application number
TW109136022A
Other languages
English (en)
Chinese (zh)
Inventor
蓋瑞 葛立克
安東尼 W 二世 歐皮派瑞
Original Assignee
美商費斯特威弗生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商費斯特威弗生技股份有限公司 filed Critical 美商費斯特威弗生技股份有限公司
Publication of TW202128610A publication Critical patent/TW202128610A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW109136022A 2019-10-18 2020-10-16 醫藥調配物 TW202128610A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962923290P 2019-10-18 2019-10-18
US62/923,290 2019-10-18

Publications (1)

Publication Number Publication Date
TW202128610A true TW202128610A (zh) 2021-08-01

Family

ID=75492817

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109136022A TW202128610A (zh) 2019-10-18 2020-10-16 醫藥調配物

Country Status (9)

Country Link
US (1) US20210114973A1 (OSRAM)
EP (1) EP4045480A4 (OSRAM)
JP (1) JP2022553934A (OSRAM)
KR (1) KR20240039083A (OSRAM)
CN (1) CN117597327A (OSRAM)
AR (1) AR122323A1 (OSRAM)
CA (1) CA3157861A1 (OSRAM)
TW (1) TW202128610A (OSRAM)
WO (1) WO2021076922A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768937A (zh) * 2021-11-15 2021-12-10 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物
US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529393A (ja) 2014-09-12 2017-10-05 アンティバイオティクス エーピーエスAntibiotx Aps ハロゲン化サリチルアニリドの抗菌用途
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
AU2016315852B2 (en) 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US20230107927A1 (en) * 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
GB202301306D0 (en) * 2023-01-30 2023-03-15 Ucl Business Ltd Treatment of granulomatous disease
CN117357523A (zh) * 2023-10-25 2024-01-09 澳门大学 利拉萘酯在制备预防和治疗肺纤维化药物中的用途
CN117466786A (zh) * 2023-12-25 2024-01-30 湖南一格制药有限公司 盐酸戊乙奎醚杂质及其制备方法
WO2025207484A1 (en) * 2024-03-25 2025-10-02 Merveille.Ai Use of aprepitant and cyclic dipeptide for weight control
CN118649135B (zh) * 2024-07-18 2024-12-10 广东药科大学 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法
CN119525016B (zh) * 2024-12-24 2026-04-07 中国矿业大学 一种组合捕收剂及其在钾长石反浮选脱硅中的应用
CN119431243B (zh) * 2025-01-09 2025-06-10 万邦德制药集团有限公司 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用
CN119841970B (zh) * 2025-01-23 2026-02-27 集美大学 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用
CN121406752A (zh) * 2025-12-26 2026-01-27 圣湘生物科技股份有限公司 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557615C2 (de) * 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
CN1546919A (zh) * 2003-07-13 2004-11-17 叶声羽 桑拿浴房
CN1626506A (zh) * 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN103751854B (zh) * 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
AU2016315852B2 (en) * 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
EP3168211A1 (en) * 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11746088B2 (en) 2020-05-19 2023-09-05 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11834410B2 (en) 2020-05-19 2023-12-05 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11958807B2 (en) 2020-05-19 2024-04-16 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12110272B2 (en) 2020-05-19 2024-10-08 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12291499B2 (en) 2020-05-19 2025-05-06 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN113768937A (zh) * 2021-11-15 2021-12-10 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物

Also Published As

Publication number Publication date
WO2021076922A1 (en) 2021-04-22
US20210114973A1 (en) 2021-04-22
JP2022553934A (ja) 2022-12-27
KR20240039083A (ko) 2024-03-26
EP4045480A4 (en) 2023-11-22
CA3157861A1 (en) 2021-04-22
CN117597327A (zh) 2024-02-23
EP4045480A1 (en) 2022-08-24
AR122323A1 (es) 2022-08-31

Similar Documents

Publication Publication Date Title
JP7189983B2 (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
US11564896B2 (en) Methods of treatment
KR20240039083A (ko) 약제학적 제형
TW202200121A (zh) 治療方法
US20230102999A1 (en) Deuterated niclosamide
US10336777B2 (en) Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use